Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall.

@article{McGough2003PharmacokineticsOS,
  title={Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall.},
  author={James J. McGough and Joseph Biederman and Laurence Lee Greenhill and James Thomas Mccracken and Thomas J. Spencer and Kelly L Posner and Sharon B. Wigal and Jeffrey A. Gornbein and Simon M. Tulloch and James M. Swanson},
  journal={Journal of the American Academy of Child and Adolescent Psychiatry},
  year={2003},
  volume={42 6},
  pages={
          684-91
        }
}
OBJECTIVE To assess the pharmacokinetic (PK) properties of a single daily dose of Adderall (mixed amphetamine salts) and the extended-release formulation, SLI381 (ADDERALL XR), in pediatric attention-deficit/hyperactivity disorder (ADHD). METHOD Fifty-one children (aged 6-12 years) with ADHD participated in a 6-week, seven-visit, PK and pharmacodynamic study. PK sampling occurred during visit 1 and again at visit 7. At visit 1, subjects received an initial oral dose of SLI381, 20 mg. At visit… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Similar Papers

Loading similar papers…